CClinicalTrials.gg
CompletedNCT01235208Updated Aug 15, 2012

The Effect of the Treatment Program "Dr. Fedon Lindbergs Vektcoach" on Body Weight and Composition and Hormonal Profile

An interventional study of The "Dr. Fedon Lindbergs Vektcoach" Treatment in Overweight, Obesity and Metabolic Syndrome, sponsored by Eurodiet Scandinavia AS. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-15.

Sponsored by Eurodiet Scandinavia AS · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The background for the trial is a number of previous studies indicating that it is especially important to restrict the intake of carbohydrates when treating overweight and metabolic diseases in general.

The purpose of the study is to obtain research data on the effects of an established treatment of overweight/obesity and its related metabolic disorders. The treatment, "Dr. Fedon Lindbergs Vektcoach", is a combination treatment where patients use low carbohydrate and low energy "Eurodiet" products in the initial phases. After the initial phases are completed, low glycemic normal foods are added to the diet until a sustainable and healthy diet is achieved. The treatment is of 7 month duration.

02

Conditions studied

  • Overweight
  • Obesity
  • Metabolic Syndrome

Keywords

  • Overweight
  • Obesity
  • Metabolic syndrome
  • Diet
  • Carbohydrate
  • Low glycemic index
  • Eurodiet
03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.

This study's enrollment of 44 is below the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

This is the only study on the registry with Eurodiet Scandinavia AS as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Body Mass Index (BMI)>35
  • BMI>27 + one risk factor for cardiovascular disease or metabolic syndrome
  • >18 years

Exclusion criteria

Exclusion Criteria:

  • Medicinal treatment of thyroid disease
  • Pregnancy or planned pregnancy
  • Taking of diet pills like Xenical or Sibutramine
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Eurodiet treatment

    Other: The "Dr. Fedon Lindbergs Vektcoach" Treatment

Interventions

  • OtherThe "Dr. Fedon Lindbergs Vektcoach" Treatment

    Diet and lifestyle treatment

06

What researchers measure

Primary outcomes

  1. Body weight/composition

    Time frame: 7 months

Secondary outcomes

  1. Hormonal profile

    Time frame: 7 months

07

Study locations

1 site
  • Dr. Fedon Lindbergs Klinikk
    Oslo, Norway
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01235208
Lead sponsor
Eurodiet Scandinavia AS
Responsible party
Sponsor
First posted
Nov 5, 2010
Start date
Oct 2010
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Aug 15, 2012

Study contacts

Pål T Jåbekk, M.Sc
principal investigator
Arne T Høstmark, Ph.D/Dr.Med
study director · Unaffiliated/ Study supervisor

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion